| Application | Recommended Dilution |
|---|---|
| FC | 1:50-1:200 |
FCGR2B, also known as CD32B, serves as a critical inhibitory receptor in the immune system, functioning as the low-affinity receptor for the Fc region of immunoglobulin G. This receptor plays a pivotal role in modulating immune responses by setting activation thresholds on B cells, regulating antibody production, and preventing autoimmunity. Its involvement in immune checkpoint signaling and potential as a therapeutic target has made FCGR2B a focus of intense research in autoimmune disease, cancer immunology, and antibody-based drug development.
This recombinant monoclonal antibody, clone 25B7, offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures that every lot performs identically to the last, eliminating the variability that can compromise longitudinal studies or require repeated optimization. The human IgG1 isotype format provides additional versatility for researchers working with human immune cell populations.
Validation studies using flow cytometry demonstrate clear detection of FCGR2B on Raji cells, a well-characterized B cell lymphoma line known to express this receptor. Surface staining at a 1:100 dilution produced distinct separation from isotype control, confirming specific recognition of the target on human cells. The antibody has been validated for both ELISA and flow cytometry applications, with recommended dilutions of 1:50-1:200 for flow cytometric analysis, giving researchers flexibility in optimizing signal intensity for their specific experimental conditions.
This antibody supports investigations into B cell biology, Fc receptor signaling pathways, immune regulation mechanisms, and the development of therapeutic antibodies where FCGR2B engagement influences efficacy and safety profiles.
Email: support@cusabio.com
Distributors Worldwide